Mostrando 4 resultados de: 4
Filtros aplicados
Publisher
Anales del Sistema Sanitario de Navarra(1)
International Journal of Molecular Sciences(1)
Journal of Diabetes Research(1)
Nutrients(1)
Origen
scopus(4)
Pathogenic mechanisms of SARS-CoV-2 infection and kidney disease: a clinical and molecular perspective
ArticleAbstract: The SARS-CoV-2 infection has become as a worldwide public health emergency. It exhibits a variety ofPalabras claves:acute kidney injury, Angiotensin-conver-ting enzyme 2, Chronic kidney disease, covid-19, SARS-COV-2Autores:D’marco L., Guerra-Torres X.E., Lameda V., Manzano A., Medina O., Morillo V., Nava M., Parra H., Puchades M.J., Suarez M.K., Torres W., Valmore BermúdezFuentes:scopusMetabolic syndrome: Is it time to add the central nervous system?
ReviewAbstract: Metabolic syndrome (MS) is a set of cardio-metabolic risk factors that includes central obesity, hypPalabras claves:Alzheimer’s disease, Diabetes mellitus type 2, Insulin Resistance, Metabolic syndrome, Mild cognitive impair-mentAutores:Añez-Ramos R., Chávez-Castillo M., Dávila L.C.A., Díaz-Camargo E.A., Durán-Agüero S., González M.C., Gravini-Donado M., Nava M., Parra H., Pírela D., Rina Ortiz, Rojas M., Salazar-Vílchez J., Valmore BermúdezFuentes:scopusRole of endocrine-disrupting chemicals in the pathogenesis of non-alcoholic fatty liver disease: A comprehensive review
ReviewAbstract: Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disorder, affecting arPalabras claves:Endocrine-disrupting chemicals, Environmental pollutants, Exposure, Liver disorder, Non-alcoholic fatty liver diseaseAutores:Cano G., Cano R.A., Dávila L.C.A., Diaz M.P., Gomez Y., González M.C., Manzano A., Ortega A., Parra H., Pérez J.L., Rojas-Quintero J., Valero-Cedeño N.J., Valmore Bermúdez, Veliz T.Fuentes:scopusSGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
ReviewAbstract: Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) aPalabras claves:Autores:D’marco L., Morillo V., Nava M., Ortega A., Parra H., Rojas-Quintero J., Suarez M.K., Teruel J.L., Valmore Bermúdez, Villasmil N.Fuentes:scopus